Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

被引：0
|
作者：
Fang, Y. [1 ]
Pan, H. [1 ]
Shou, J. [2 ]
Hong, W. [3 ]
Yang, X. [4 ]
Zhu, D. [5 ]
Zhou, Y. [6 ]
Lan, F. [7 ]
Rao, C. [8 ]
Chen, J. [9 ]
机构：
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China
[3] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
[4] First Hosp Jiaxing, Jiaxing, Peoples R China
[5] Jinhua Municipal Cent Hosp, Jinhua, Zhejiang, Peoples R China
[6] Cent Hosp Lishui City, Lishui, Peoples R China
[7] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[8] Univ Chinese Acad Sci, Hwa Mei Hosp, Ningbo, Peoples R China
[9] Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Anlotinib; NSCLC; anti-angiogenesis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P86.22
引用
收藏
页码：S682 / S682
页数：1
相关论文
共 50 条
  • [1] Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.
    Fang, Yong
    Pan, Hongming
    Shou, Jiawei
    Hong, Wei
    Guo, Qunyi
    Yang, Xinmei
    Zhu, Dan
    Chen, Jun
    Lu, Liqin
    Rao, Chuangzhou
    Lan, Fen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
  • [3] Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial.
    Pectasides, D
    Farmakis, D
    Pectasides, M
    Kostopoulou, V
    Nikolaou, M
    Koumpou, M
    Gaglia, A
    Kountourakis, P
    Mylonakis, N
    Economopoulos, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
  • [4] Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC)
    Leighl, N
    Laurie, S
    Knox, J
    Ellis, P
    Shepherd, F
    Burkes, R
    Pond, G
    Zwiebel, J
    Moore, M
    LUNG CANCER, 2005, 49 : S256 - S256
  • [5] The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.
    Xu, Zhiqiao
    Zhang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Anlotinib plus docetaxel vs. docetaxel as 2nd-line treatment of advanced non-small cell lung cancer (NSCLC): Updated results from ALTER-L016
    Fang, Y.
    Pan, H.
    Shou, J.
    Chen, J.
    Guo, Q.
    Hong, W.
    Rao, C.
    Wang, Y.
    Lu, L.
    Yang, X.
    Zhu, D.
    Lan, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1029 - S1029
  • [7] Docetaxel followed by gemcitabine in the treatment of advanced non-small cell lung cancer: A phase I study
    Frassineti, GL
    Ibrahim, T
    Zoli, W
    Monti, M
    Ricotti, L
    Nanni, O
    Amadori, D
    TUMORI JOURNAL, 2002, 88 (02): : 99 - 103
  • [8] A phase I/II study of oxaliplatin and docetaxel in the treatment of relapsed non-small cell lung cancer
    Graham, D.
    Delaney, H.
    OConnor, F.
    Buckley, H.
    Gately, K.
    OByrne, K.
    EJC SUPPLEMENTS, 2009, 7 (02): : 532 - 532
  • [9] Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    Kotsakis, Athanasios
    Hatzidaki, Dora
    Syrigos, Kostas
    Polyzos, Aris
    Agelidou, Athina
    Varthalitis, Loannis
    Ziras, Nikoalos
    Agelidou, Maria
    Chandrinos, Vassilis
    Boukovinas, Loannis
    Geroyianni, Alexandra
    Vamakas, Larnbros
    Mavroudis, Dirnitris
    LUNG CANCER, 2008, 59 (01) : 57 - 63
  • [10] Phase II trial of docetaxel and carboplatin in the treatment of advanced non-small cell lung cancer
    Schutte, W
    Bork, I
    Wollschlager, B
    Schadlich, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1076 - 1076
12345